AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXPRNewsWire • 03/30/24
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxPRNewsWire • 03/29/24
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersPRNewsWire • 03/29/24
Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXAccesswire • 03/29/24
Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – AMLXAccesswire • 03/29/24
Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAccesswire • 03/28/24
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) ShareholdersAccesswire • 03/28/24
Amylyx Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLXAccesswire • 03/28/24
Shareholders that lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact Levi & Korsinsky about pending Class Action - AMLXAccesswire • 03/28/24
ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXPRNewsWire • 03/27/24
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit – AMLXAccesswire • 03/27/24
DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/26/24
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXPRNewsWire • 03/26/24
Contact Levi & Korsinsky by April 9, 2024 Deadline to Join Class Action Against Amylyx Pharmaceuticals, Inc.(AMLX)Accesswire • 03/25/24
Investors who lost money on Amylyx Pharmaceuticals, Inc.(AMLX) should contact Levi & Korsinsky about pending Class Action - AMLXAccesswire • 03/25/24
INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINEPRNewsWire • 03/25/24
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/25/24
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 03/24/24
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXPRNewsWire • 03/23/24
The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming DeadlinePRNewsWire • 03/22/24
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLXAccesswire • 03/21/24
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLXPRNewsWire • 03/20/24
Shareholders That Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX) Should Contact Levi & Korsinsky About Pending Class Action - AMLXAccesswire • 03/20/24
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLXAccesswire • 03/20/24
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLXPRNewsWire • 03/19/24
